Clinical Trial Update: Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) [Phase 1, Phase 2]

View source ↗

Summary

This document describes an ongoing Phase 1/2 clinical trial evaluating the safety, tolerability, and preliminary efficacy of intravitreal ABI-110 (AAV2.N54-VEGF…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration
• Polypoidal Choroidal Vasculopathy

Drugs mentioned

• ABI-110 (AAV2.N54-VEGF Trap)

Snippet

Sponsor: Avirmax Biopharma Inc | Conditions: Neovascular (Wet) AMD | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING